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Abstract
Background: Serum gamma-glutamyltransferase (GGT) activity is a sensitive
but non-specific marker of non-alcoholic fatty liver disease (NAFLD).
Recently, four GGT fractions (big-, medium-, small-, free-GGT) were
described in humans. Aim: We aimed to investigate whether a specific GGT
fraction pattern is associated with NAFLD. Methods: Gamma-glutamyl-
transferase fractions were determined in patients with NAFLD (n = 90), and
compared with those in control subjects (n = 70), and chronic hepatitis C
(CHC, n = 45) age and gender matched. Results: Total GGT was elevated in
NAFLD as compared to controls (median, 25°–75°percentile: 39.4, 20.0–
82.0 U/L vs. 18.4, 13.2–24.9 U/L respectively, P < 0.001). All fractions were
higher in NAFLD than in controls (P < 0.001). The b-GGT showed the high-
est diagnostic accuracy for NAFLD diagnosis [area under ROC curve (ROC-
AUC): 0.85; cut-off 2.6 U/L, sensitivity 74%, specificity 81%]. Also subjects
with CHC showed increased GGT (41.5, 21.9–84.5 U/L, P < 0.001 vs. con-
trols, P = n.s. vs. NAFLD), as well as m-, s-, and f-GGT, while b-GGT did
not show any significant increase (P = n.s. vs. HS, P < 0.001 vs. NAFLD). In
subjects with CHC, s-GGT showed the best diagnostic value (ROC-AUC:
0.853; cut-off 14.1 U/L, sensitivity 73%, specificity 90%). Serum GGT did
not show any value in the differential diagnosis between NAFLD and CHC
(ROC-AUC 0.507, P = n.s.), while b-GGT/s-GGT ratio showed the highest
diagnostic accuracy for distinguishing NAFLD and CHC (ROC-AUC: 0.93;
cut-off value 0.16, sensitivity 82%, specificity 90%). Conclusions: b-GGT
increases in NAFLD, but not in CHC. GGT fraction analysis might help in
improving the sensitivity and specificity of the diagnosis of NAFLD and other
liver dysfunctions.
Non-alcoholic fatty liver disease (NAFLD) is emerging
as a major cause of liver disease in Western countries
(25% of the adult populations) encompassing a spec-
trum of pathologic variants including simple steatosis as
well as non-alcoholic steatohepatitis (3–6%) (1, 2).
Non-alcoholic fatty liver disease may evolve into
advanced fibrosis, cirrhosis, end-stage liver disease,
hepatocarcinoma (1), it is now recognized as the
hepatic manifestation of the metabolic syndrome being
associated with insulin resistance, type 2 diabetes and
atherogenic dyslipidaemia (3), and increased risk for
cardiovascular events (4).
The lack of accurate humoral biomarkers represents a
major obstacle to the diagnosis and prevention of
NAFLD, which relies mainly on ultrasonography,
because of the risks and costs associated with liver
biopsy. In fact, although NAFLD is associated with
increased level of aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), triglycerides, none of
these markers have high specificity for the disease (5, 6).
Serum gamma-glutamyltransferase (GGT) activity is
a sensitive marker of liver dysfunction, but its specificity
is modest, as its value increases with common condi-
tions causing liver dysfunction (7), such as steatosis
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(8, 9) and viral hepatitis (10). GGT value has been
already included in diagnostic algorithm (i.e. the Fatty
Liver Index, FLI) to test the presence of steatosis and its
specificity was high if considered with other markers,
but low if considered alone (11).
In patients with chronic viral hepatitis C (CHC) (10),
GGT elevation has been correlated with more severe
hepatic fibrosis (12, 13). In fact its value has been
included in a multimarker algorithm, named FibroTest,
recently proposed in CHC patients as surrogate index of
fibrosis (14), as a valid alternative to liver biopsy, espe-
cially to monitor disease progression (15, 16).
A new method based on molecular-size exclusion
chromatography, followed by a GGT-specific post-
column reaction, allowed to identify and quantify, in
healthy subjects (HS), four plasma GGT fractions with
high sensitivity, specificity and reproducibility (17, 18).
These fractions, named big-GGT (b-GGT), medium-
GGT (m-GGT), small-GGT (s-GGT) and free-GGT
(f-GGT) showed different molecular weight, i.e. 2000,
1000, 250 and 70 kDa respectively (17). We have previ-
ously shown that in HS f-GGT is the most abundant
fraction, while b-GGT showed the highest degree of cor-
relation with established cardiovascular risk factors,
such as level of serum triglycerides, LDL-cholesterol,
C-reactive protein, diastolic blood pressure (19). Inter-
estingly b-GGT has been found in atherosclerotic
plaques together with products deriving from the pro-
oxidant reactions catalysed by the enzyme, suggesting
that only b-GGT, rather than total serum GGT itself, is
responsible of the association between serum GGT and
cardiovascular disease in population and clinical studies
(20).
This study was aimed to test the hypothesis that a
specific GGT fraction pattern might be associated
with NAFLD, in order to improve its diagnosis and
contribute to understanding the relationship between
NAFLD, the so-called metabolic syndrome, and the risk
of cardiovascular disease.
Patients and methods
Patient selection
Ninety consecutive patients diagnosed with NAFLD,
and 45 consecutive patients with CHC were enrolled in
the study at the Department of Internal Medicine of the
University of Pisa. Seventy HS were selected out of 256
blood donors already characterized and studied for the
determination of fractional GGT reference values (18),
to obtain a cohort matched for age and gender with
NAFLD and CHC patients. The baseline characteristics
of patient cohorts and HS are presented in Table 1.
Non-alcoholic fatty liver disease was diagnosed on the
basis of liver ultrasonography, after thorough exclusion
of other sources of liver disease. In subjects with anti-
HCV antibodies, viral infection was confirmed by HCV-
RNA assessment. The alcohol consumption was assessed
Table 1. Baseline characteristics of patients with non-alcoholic fatty liver disease (NAFLD), chronic viral hepatitis C (CHC) and healthy sub-
jects (HS)
NAFLD (n = 90) CHC (n = 45) HS (n = 70)
P
NAFLD vs. CHC
P
NAFLD vs. HS
P
CHC vs. HS
N males (%) 90 (72) 45 (49) 70 (70) <0.05 n.s. n.s.
Age, years 56.8 (12.4) 62.3 (13.7) 56.6 (6.5) <0.05 n.s. <0.001
BMI, kg/m2 29.4 (6.1) 25.7 (3.5) 25.2 (2.8) <0.01 <0.001 n.s.
Diabetes, n (%)* 18 (20.0) 1 (2.2) 0 <0.05 <0.001 n.s.
Hypertension, n (%)* 44 (48.8) 3 (6.7) 0 <0.001 <0.001 n.s.
Glucose, mg/dl 101.0 (29.1) 92.0 (19.1) 97.8 (9.6) n.s. n.s. n.s.
Creatinine, mg/dl 1.1 (0.5) 0.8 (0.2) 0.9 (0.2) n.s. n.s. n.s.
eGFR, ml/min/1.73 m2 153.2 (53.0) 80.2 (23.3) 93.4 (22.1) n.s. <0.001 <0.001
Total cholesterol, mg/dl 218.8 (56.9) 170.1 (31.3) 199.4 (34.2) <0.001 <0.05 <0.01
HDL cholesterol, mg/dl 45.0 (14.8) 53.1 (16.3) 57.0 (13.7) <0.05 <0.001 n.s.
LDL cholesterol, mg/dl 142.8 (48.8) 100.6 (28.9) 129.4 (34.0) <0.001 n.s. <0.01
Triglycerides†, mg/dl 167.8 (104.3) 101.2 (47.6) 83.5 (28.2) <0.001 <0.001 n.s.
AST, U/L 28.9 (30.4) 59.0 (41.2) 18.9 (4.4) <0.001 n.s. <0.001
ALT, U/L 40.7 (43.1) 57.8 (44.7) 18.5 (5.9) <0.05 <0.001 <0.001
Total bilirubin, mg/dl 0.75 (0.29) 0.82 (0.54) 0.85 (0.46) n.s. n.s. n.s.
Direct bilirubin, mg/dl 0.16 (0.09) 0.29 (0.21) 0.13 (0.05) <0.01 n.s. <0.001
Haemoglobin, g/dl 9.8 (16.8) 13.3 (1.6) 14.9 (1.1) <0.01 n.s. <0.01
Leucocytes, x109 L 6.7 (1.6) 5.2 (1.5) 6.1 (1.4) <0.001 <0.05 <0.05
*Chi-squared test.
†Statistical analysis performed on ln-transformed data.
Data are reported as means (SD). AST, aspartate amino transferase; ALT, alanine amino transferase; BMI, body mass index; eGFR, estimated glomerula
filtration rate; GGT, gamma-glutamyltransferase. eGFR has been estimated by MDRD formula; LDL cholesterol has been estimated by the Friedewald
formula. Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparison test. n.s., not significant.
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by a direct interview of the participants to establish the
amount and the modality of alcohol consumption.
According to World Health Organisation recommenda-
tions concerning hazardous alcohol consumption,
subjects assuming more than 45 g/day (men) or 30 g/
day (women) were excluded from the study (21).
The Institutional Ethics Committee approved the
study and all subjects gave informed consent.
Laboratory analyses
Standard assay of all blood tests including serum GGT
were simultaneously performed according to the stan-
dard clinical laboratory procedures by automated analy-
sers (Beckman Synchron CX 9- PRO analyser, Beckman
Coulter, Brea, CA, USA; Abbott Cell-Dyn Sapphire for
blood cell count, Abbott Laboratories, Libertyville, IL,
USA). Estimated glomerular filtration rate (eGFR) was
estimated by the MDRD (Modification of Diet in Renal
Disease) formula [eGFR ml/min/1.73 m2 = 186.3 9 Cre-
atinine1.154 9 age0.203 9 0.742 (if woman)]; LDL cho-
lesterol was calculated using the Friedewald formula
[LDL-C = total cholesterolHDL cholesterol(trigly-
cerides/5)].
Gamma-glutamyltransferase fraction analysis
Analysis of total and fractional GGT was performed, as
previously described (17, 18), on plasma-ethylenedia-
mine-tetra-acetic acid samples using a fast protein liquid
chromatography system (AKTA purifier; GE Healthcare
Europe, Milan, Italy) equipped with a gel-filtration col-
umn (Superose 6 HR 10/300 GL; GE Healthcare Europe)
and a fluorescence detector (Jasco FP-2020; Jasco Eur-
ope, Lecco, Italy). Separation of fractional GGT was
obtained by gel-filtration chromatography and the enzy-
matic activity was quantified by post-column injection of
the fluorescent substrate for GGT, gamma-glutamyl-7-
amido-4-methylcoumarin (gGluAMC). Enzymatic reac-
tion, in the presence of gGluAMC 0.030 mmol/L and
glycylglycine 4.5 mmol/L, proceeded for 4.5 min in a
reaction coil (PFA, 2.6 mL) kept at the 37°C in a water
bath. The fluorescence detector operating at excitation/
emission wavelengths of 380/440 nm detected the AMC
signal; the intensity of the fluorescence signal was
expressed in arbitrary fluorescence units. Under this
reaction conditions, area under curve (AUC) is propor-
tional to GGT activity. Fractional GGT activity was quan-
tified as previously described (18). The overall cost per
sample for fractional GGT analysis is 4 euro (5.56$),
including cost of consumables 2.62 euro (3.64$)/sample.
Statistical analysis
Statistical analysis was conducted by one-way ANOVA
analysis followed by Tukey’s multiple comparison
test. Total, b-, m- and s-GGT, as well as b/s ratio and
triglyceride values were ln-transformed to reduce the
distribution skewness. Proportion of diabetes and
hypertension among the three groups was compared by
the chi-squared test.
Receiver operating characteristics curve analysis
(ROC) was performed to establish the diagnostic power
of total and fractional GGT and of the b-GGT/s-GGT
ratio values. In fact, ROC analysis provided the AUC
values, which define the increment in predictive power
between variables, as well as corresponding sensitivity,
specificity, positive and negative predictive values and
the optimum cut-off values (at the point of ROC corre-
sponding to maximal sum of specificity and sensitivity).
ROC analysis and the comparison between ROC curves
were performed with MEDCALC 11.5 analysis software on
the basis of the De Long method (22).
Results
Patients’ characteristics
No difference was found among patients with NAFLD,
CHC and controls as concerns the level of serum glu-
cose, creatinine and total bilirubin. As expected, patients
with NAFLD showed significantly higher level of BMI
(P < 0.001), total cholesterol (P < 0.05), triglycerides
(P < 0.001), ALT (P < 0.001), and lower values of HDL
cholesterol (P < 0.001), as compared to HS (Table 1).
As compared to NAFLD, CHC patients showed higher
values of HDL cholesterol, AST and ALT, and lower
LDL cholesterol and triglycerides.
Serum GGT values in NAFLD and CHC were very
similar and significantly higher than in HS (P < 0.001)
(Table 2).
Fractional gamma-glutamyltransferase analysis
The b-GGT fraction in NAFLD patients was higher than
in CHC patients (P < 0.001) and HS (P < 0.001)
(Table 2). m-GGT, s-GGT and f-GGT fractions were all
significantly higher in NAFLD (P < 0.001) and CHC
(P < 0.05, <0.001, <0.01, respectively) as compared to
HS (Table 2), while no difference was seen between
NAFLD and CHC patients. Because of the concomitant
increase of b-GGT and s-GGT in NAFLD, the b/s ratio
in NAFLD was not significantly different than that in
HS, but significantly higher than in CHC (P < 0.001).
Diagnostic value of fractional gamma-glutamyltransferase:
receiver operating characteristic curve analysis
In ROC analysis, b-GGT showed the greatest accuracy
for the NAFLD diagnosis among fractions (cut-off:
2.6 U/L; P = 0.02 vs. s-GGT, P < 0.001 vs. m-GGT,
f-GGT), while s-GGT showed a higher accuracy for the
diagnosis of CHC (cut-off: 14.1 U/L; P < 0.0001 vs. all
the other fractions) (Tables 3 and 4).
The b/s ratio showed at a same time the highest diag-
nostic accuracy for CHC (cut-off: 0.16; P < 0.0001 vs.
Liver International (2012)
© 2011 John Wiley & Sons A/S 631
Franzini et al. NAFLD diagnosis: accuracy of b-GGT
Table 3. Results of the receiver operating characteristic curve analysis
HS (N = 70) VS. NAFLD (N = 90) HS (N = 70) VS. CHC (N = 45) NAFLD (N = 90) VS. CHC (N = 46)
Total GGT 0.807* (0.737–0.865) 0.803* (0.718–0.871) 0.507n.s. (0.419–0.694)
b-GGT 0.850* (0.785–0.901) 0.601n.s. (0.506–0.692) 0.743* (0.661–0.814)
m-GGT 0.743* (0.688–0.809) 0.662‡ (0.568–0.748) 0.554n.s. (0.466–0.640)
s-GGT 0.788* (0.716–0.848) 0.853* (0.774–0.912) 0.573n.s. (0.485–0.658)
f-GGT 0.726* (0.650–0.793) 0.689† (0.596–0.772) 0.557n.s. (0.469–0.643)
b/s ratio 0.555n.s. (0.474–0.633) 0.912* (0.845–0.957) 0.931* (0.874–0.967)
AST 0.722* (0.644–0.790) 0.899* (0.827–0.948) 0.796* (0.716–0.862)
ALT 0.793* (0.721–0.853) 0.879* (0.804–0.933) 0.657‡ (0.568–0.738)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHC, patients with chronic hepatitis HCV related; NAFLD, patients with non-alco-
holic fatty liver disease; n.s., not significant; ROC-AUC, area under receiver operating characteristic curve.
Data are ROC-AUC (95% CI).
*P < 0.0001;
†P < 0.001;
‡P < 0.01.
Table 2. Total and fractional gamma-glutamyltransferase (GGT) activity (U/L) in plasma of patients with non-alcoholic liver disease (NAFLD),
chronic viral hepatitis C (CHC) and healthy subjects (HS)
NAFLD (n = 90) CHC (n = 45) HS (n = 70)
P
NAFLD vs. CHC
P
NAFLD vs. HS
P
CHC vs. HS
Total GGT* 39.4 (20.0–82.0) 41.5 (21.9–84.5) 18.4 (13.2–24.9) n.s. <0.001 <0.001
b-GGT* 5.1 (2.5–14.9) 2.1 (1.2–5.3) 1.7 (1.0–2.4) <0.001 <0.001 n.s.
m-GGT* 1.7 (0.6–3.7) 1.2 (0.4–3.7) 0.6 (0.4–0.9) n.s. <0.001 <0.05
s-GGT* 14.9 (5.9–43.5) 22.9 (10.0–59.6) 4.7 (2.9–8.9) n.s. <0.001 <0.001
f-GGT 14.2 (10.3–18.6) 13.8 (9.3–16.9) 9.9 (8.4–12.2) n.s. <0.001 <0.01
b/s ratio* 0.37 (0.24–0.51) 0.10 (0.07–0.15) 0.32 (0.22–0.48) <0.001 n.s. <0.001
Total and fractional GGT data are presented as median (25th–75th percentile).
*One-way ANOVA followed by Tukey’s multiple comparison test performed on ln-transformed data.
n.s., not significant.
Table 4. Diagnostic values for total and fractional gamma-glutamyltransferase (GGT) for the diagnosis of non-alcoholic fatty liver disease
(NAFLD) and chronic viral hepatitis C (CHC)
Cut-off Sensitivity % (95% CI) Specificity % (95% CI) PPV% NPV%
NAFLD vs. CHC
Total-GGT* 13.3 U/L 11.1 (3.7–24.1) 98.9 (94.0–100.0) 83.3 69.0
b-GGT 1.8 U/L 44.4 (29.6–60.0) 92.2 (84.6–96.8) 74.1 76.9
m-GGT* 0.5 U/L 26.7 (14.6–41.9) 86.7 (77.9–92.9) 55.0 70.3
s-GGT 14.7 U/L 71.1 (55.7–83.6) 50.0 (39.3–60.7) 41.6 77.6
f-GGT* 17.3 U/L 86.7 (73.2–94.9) 30.0 (20.8–40.6) 38.2 81.8
b/s ratio 0.15 80.0 (65.4–90.4) 92.2 (84.6–96.8) 83.7 90.2
HS vs. NAFLD
Total GGT 26.2 U/L 66.7 (55.9–76.3) 82.7 (72.0–90.8) 83.3 65.9
b-GGT 2.6 U/L 74.44 (64.2–83.1) 81.4 (79.3–89.7) 83.7 71.2
m-GGT 1.7 U/L 51.1 (40.3–61.8) 94.3 (86.0–98.4) 92.0 60.0
s-GGT 17.5 U/L 48.9 (38.2–59.7) 95.7 (88.0–99.1) 93.6 59.3
f-GGT 13.9 U/L 52.2 (41.1–62.9) 88.6 (78.7–94.9) 85.5 59.0
b/s ratio* 0.37 50.0 (39.3–60.7) 65.7 (53.4–76.6) 65.2 50.2
HS vs. CHC
Total GGT 26.2 U/L 71.1 (55.7–83.6) 82.9 (72.0–90.8) 72.7 81.7
b-GGT* 2.7 U/L 44.4 (29.6–60.0) 82.86 (72.0–90.8) 62.5 69.9
m-GGT 1.9 U/L 42.2 (27.7–57.8) 97.1 (90.1–99.7) 90.5 72.3
s-GGT 14.1 U/L 73.3 (58.1–85.4) 90.0 (80.5–95.9) 82.5 84.0
f-GGT 14.3 U/L 46.7 (31.7–62.1) 90.0 (80.5–95.9) 75.0 72.4
b/s ratio 0.16 82.2 (67.9–92.0) 90.0 (80.5–95.9) 84.1 88.7
*ROC-AUC was not significantly different from 0.5, see Table 3. HS, healthy subjects; NPV, negative predictive value; PV, positive predictive value.
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b-GGT, m-GGT, f-GGT, p = 0.060 vs. s-GGT) and for
the differential diagnosis between NAFLD and CHC
(cut-off: 0.15; P < 0.001 vs. all GGT fractions) (Tables 3
and 4).
Although also ALT showed a high ROC-AUC
(Table 3) for the diagnosis of NAFLD and CHC, it
showed a diagnostic power significantly lower than b/s
ratio (P < 0.0001) in the differential diagnosis between
the two conditions.
Discussion
The main finding of this study is that patients with
NAFLD and CHC display different GGT fraction pat-
terns, despite similar total GGT activity values.
Among all the GGT fractions, b-GGT provided the
best specificity and sensitivity for the diagnosis of
NAFLD, with an accuracy equivalent or even greater to
those provided by available diagnostic algorithms such
as SteatoTest (ROC-AUC 0.79, SE 0.03) (23) or FLI
(ROC-AUC 0.85, 95% CI 0.81–0.88) (11). Interestingly,
these algorithms include total serum GGT activity and it
is likely that replacing GGT with b-GGT would increase
their sensitivity and specificity.
In subjects with CHC, b-GGT did not show any
significant change, while s-GGT showed a prominent
increase, thus suggesting that the ratio between these
fractions was a key aspect of the disease-associated GGT
fraction pattern. For this reason, although the study was
not originally designed to test the diagnostic value of
the ratios between GGT fractions, the diagnostic value
of the b/s ratio was tested, and indeed showed the high-
est specificity for distinguishing between CHC and NA-
FLD, as well as for the diagnosis of CHC as compared to
total GGT and all individual fractions. All other ratios
between the remaining fractions were also tested, but
their ROC-AUCs were significantly lower (not shown).
Although an obvious consideration is that the
diagnosis of CHC relies on virological tests, rather than
on serum enzymes, these findings for the first time open
the perspective of a positive diagnosis of NAFLD that
might be helpful as a screening test or to perform large
population studies on the prevalence of NAFLD and
related diseases.
The precise nature of GGT fractions has not yet been
established, and at present it is not possible to speculate
on the possible reasons conducting to different GGT
fraction patterns in NAFLD and CHC. The fact that in
NAFLD the increase of serum GGT occurs through a
proportional increase of b-GGT and s-GGT, while in
viral hepatitis occurs through a prominent increase of
s-GGT suggests that GGT fraction pattern specificity
might depend on its ability to reflect the different
extents of inflammatory, structural and functional
derangement in liver disease.
On the basis of the present results, further studies on
larger population will show if GGT fraction analysis
might also be used to identify subjects with NAFLD pro-
gressing towards parenchymal inflammation and fibro-
sis, which might experience a progressive decrease of the
b/s ratio.
The use of GGT fractional analysis might also
contributes to the understanding of the complex
epidemiological association between serum GGT,
NAFLD and cardiovascular disease (9). In fact, during
the last decade, large population studies have shown
that serum GGT (independently from alcohol consump-
tion) is one of the strongest predictors of metabolic syn-
drome (4, 24), diabetes (25, 26) as well as final events
(myocardial infarction and stroke) associated with the
atherosclerotic disease (27–29), thus opening new per-
spectives as concerns the association between liver dam-
age, metabolism and atherosclerosis. We showed that
GGT activity, in the presence of trace iron and glutathi-
one, its physiological substrate, catalyses the production
of free radicals and reactive oxygen species, thus pro-
moting LDL oxidation in vitro (30), and we found that
human atherosclerotic plaques contain GGT activity in
correspondence of the oxidized LDL and CD68+ foam
cells (31, 32). The GGT extracted from human carotid
plaques was found to correspond in part to the human
serum b-GGT fraction (20). The fact that b-GGT, which
has a potential atherogenic role (19, 20), was found in
this study to increase specifically in NAFLD, a condition
strictly associated with metabolic syndrome, iperinsulin-
emia, and dyslipidemia (3), suggests that NAFLD act as
cardiovascular risk factor by promoting b-GGT accu-
mulation and GGT-related oxidative events within the
plaque. Thus, results of this study might help to define a
new pathway connecting dysmetabolism with cardiovas-
cular disease.
In conclusion, GGT fraction analysis revealed, in
NAFLD, a GGT fraction pattern characterized by
increased levels of all GGT fractions, including b-GGT,
which did not increase in subjects with HCV, and simi-
lar levels of serum GGT. Extensive investigation on the
diagnostic value of GGT fractions might provide a novel
diagnostic tool for liver diseases; understanding the
nature, properties, and pathophysiological variations of
GGT fraction pattern might allow a better understand-
ing of the pathogenesis of the diseases associated with
increased GGT.
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